C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
3.
METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO DOPAMINERGIC NEURAL CELLS , METHOD FOR PRODUCING CELL GROUP CONTAINING DOPAMINERGIC NEURAL CELLS, AND CELL GROUP CONTAINING DOPAMINERGIC NEURAL CELLS WHICH IS PRODUCED BY SAID METHOD
The present invention provides a method for inducing the differentiation of pluripotent stem cells into dopaminergic neural cells or a method for producing a cell group containing dopaminergic neural cells from pluripotent stem cells, each of the methods comprising: (1) bringing the pluripotent stem cells into contact with a TGFβ inhibitor, a BMP inhibitor, and/or a GSK3β inhibitor; and (2) expressing Ascl1 gene in the pluripotent stem cells.
Disclosed are compounds of following formula (I):
Disclosed are compounds of following formula (I):
Disclosed are compounds of following formula (I):
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
5.
COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR
The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afuocosylated humanized B-Ly1 antibody and a BTK inhibitor.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides a composition for improving an eye disorder, said composition comprising a roe lipid preparation which is prepared so as to provide a daily intake of approximately 100-300 mg of docosahexaenoic acid (DHA).
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and other preparations for
destroying vermin fungicides herbicides; reagent paper for
medical purposes; vitamin preparations; candy, medicated;
lozenges for pharmaceutical purposes; mint for
pharmaceutical purposes; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for human beings; dietary fibre; freeze-dried
food adapted for medical purposes; lyophilized meat adapted
for medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Beauty salon services; barbershops; providing bath houses;
massage and therapeutic shiatsu massage; chiropractic;
moxibustion; treatment for dislocated joints, sprain, bone
fractures [judo-seifuku]; bodywork therapy; acupuncture;
provision of medical and pharmaceutical information via the
Internet; provision of medical information relating to
benefits, side effects, interactions of pharmaceuticals and
medications; provision of medical information about
pharmaceutical products; medical, medicinal and
pharmaceutical consultancy; advisory services relating to
pharmaceutical products; analysis and provision of clinical
data of patients for diagnostic or treatment purpose;
provision of information relating to pharmaceuticals and
medical services through computer databases; medical testing
for the collection of medical information, analysis and
provision of medical information for diagnostic or treatment
purposes; medical testing; medical consultancy and diagnosis
via the Internet; online medical counseling services; remote
monitoring of patient health status for medical conditions;
remote monitoring of medical data for medical diagnosis and
treatment; analysis and provision of clinical data of
patients for diagnostic or treatment purpose; providing
medical information; physical examination; providing
information about pharmaceuticals, medical services or
health; consultancy services relating to medical services,
pharmaceuticals, health or dispensing of medications;
consultancy, advisory and provision of information relating
to dieting, nutritional intake or health care; consultancy,
advisory and provision of information relating to health
care; managed health care services; provision of records of
personal health information data such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or—repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or—repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
10.
METHOD FOR PREPARING DIHYDRONAPHTHALENE DERIVATIVE
An object of the present invention is to provide a method for preparing a compound (I), the method being suitable for an industrial preparation scale. For the purpose of preparing a high-purity compound (I) on an industrial scale, there is a need for a method for preparing the high-purity compound (I) at low cost with high yield. As a result of intensive investigations, the inventors of the present invention have found, in order to solve the above object, reaction conditions under which a geometric isomer of a double bond can be controlled and a preparation method for obtaining a desired isomer in a process for preparing the compound (II). In addition, in each preparation step, reaction conditions for obtaining a high-purity intermediate or the compound (I), post-treatment conditions for removing impurities, and crystallization conditions have been found. Further, a method for synthesizing the compound (I), the method allowing safe operation even at an industrial preparation scale has been found.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A compound represented by general formula (I) (wherein all symbols have the same meanings as the symbols described in the specification) or a pharmaceutically acceptable salt thereof is useful as an EP4 agonist, particularly has an EP4 agonistic activity, has selectivity for other PGE receptor subtypes, and has a smaller risk of toxicity to the circulatory system. Therefore, the compound or the pharmaceutically acceptable salt thereof is useful as a medicinal ingredient in the prevention and/or treatment of diseases associated with EP4 receptors.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
12.
NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japan)
Eisai R&D Management Co., Ltd. (Japan)
ONO PHARMACEUTICAL CO., LTD. (Japan)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japan)
Inventor
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Takado, Yuhei
Matsuoka, Kiwamu
Mizuma, Hiroshi
Yamamoto, Takeshi
Wakabayashi, Takeshi
Ohfusa, Toshiyuki
Abstract
Provided is a compound that has high binding selectivity with respect to α-synuclein aggregates.
Provided is a compound that has high binding selectivity with respect to α-synuclein aggregates.
Provided is a compound represented by the following formula (I), (II), or (III), a pharmaceutically acceptable salt thereof, or a solvate thereof.
Provided is a compound that has high binding selectivity with respect to α-synuclein aggregates.
Provided is a compound represented by the following formula (I), (II), or (III), a pharmaceutically acceptable salt thereof, or a solvate thereof.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present application provides an immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The purpose of the present invention is to provide a sepetaprost-containing eye drop having exceptional formulation stability. The present invention relates to an eye drop containing sepetaprost, the eye drop being accommodated in an ethylene-oxide-gas-sterilized eye drop container.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
C07D 313/06 - Seven-membered rings condensed with carbocyclic rings or ring systems
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Provided are an inspection system, an inspection method, and a program, all of which are for improving detection accuracy of a foreign object in a container filled with a liquid. The inspection system comprises a rotation control unit that performs control for rotating the container around a horizontal axis in a direction in which the inclination of the central axis with respect to the vertical axis increases while rotating the container around the central axis of the container filled with the liquid.
The present disclosure provides the methods for making 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid. The present disclosure also generally relates to intermediates useful in the said methods.
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
The present invention addresses the problem of providing: an antibody that recognizes an HLA-A24/HF10 peptide complex on a cancer cell surface; a pharmaceutical composition comprising the antibody, in particular, a pharmaceutical composition for treating cancer and a use thereof; and a method for treating cancer. Provided is a multispecific antibody having an antigen-binding site that recognizes a complex of a polypeptide represented by SEQ ID NO: 3 and an MHC molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
(wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 327/48 - Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations; medicines for veterinary purposes;
medicated toiletry preparations; sanitary preparations for
medical purposes; fungicides; sterilizing preparations;
disinfectants for hygiene purposes; pharmaceutical
preparations for the treatment and prevention of
cardiovascular disorders, genitourinary disorders,
gynecological diseases and obstetric diseases, cancer and
its metastasis, eye disorders, neurologic disorders,
psychiatric disorders, endocrine and metabolic disorders,
allergic disorders, gastrointestinal disorders, immune
diseases and autoimmune diseases, respiratory diseases,
musculoskeletal and connective tissue disorders, infectious
diseases, dermatologic disorders, hematological disorder,
inflammatory diseases, ear, nose, dental and throat
disorders, hepatic and biliary disorders, alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; candy, medicated;
pastilles for pharmaceutical purposes; mint for
pharmaceutical purposes; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilized food
adapted for medical purposes; lyophilized meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Beauty salon services; barber shop services; providing bath
houses; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo-seifuku]; bodywork therapy;
acupuncture; provision of medical and pharmaceutical
information via the Internet; provision of medical
information relating to benefits, side effects, interactions
of pharmaceuticals and medications; provision of medical
information about pharmaceutical products; medical,
medicinal and pharmaceutical consultancy; advisory services
relating to pharmaceutical products; provision of
information on pharmaceuticals and medical services through
computer databases; medical testing for the collection of
medical information, analysis and provision of medical
information for diagnostic or treatment purposes; medical
testing; medical consultancy and diagnosis via the Internet;
online medical counseling services; remote monitoring of
medical data for medical diagnosis and treatment; analysis
and provision of clinical data of patients for diagnostic or
treatment purpose; provision of medical information;
physical examination; providing information about
pharmaceuticals, medical services or health; consultancy
services relating to medical services, pharmaceuticals,
health or dispensing of medications; consultancy, advisory
and provision of information relating to dieting,
nutritional intake or health care; consultancy, advisory and
provision of information relating to health care; managed
health care services; provision of records of personal
health information data such as weight, body fat, body
temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
Disclosed is a compound of formula (I), wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61P 25/00 - Drugs for disorders of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
27.
HUMAN-DERIVED ANTI-COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 (CRMP2) ANTIBODIES
Collapsin Response Mediator Protein 2 (CRMP2) is established as a therapeutic target in neurodegenerative disorders. Provided are novel human-derived anti-CRMP2 antibodies as well as fragments, derivatives and variants thereof. Polynucleotides, vectors, host cells and kits related to the CRMP2 specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical compositions for CRMP2 targeted therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; glucose dietary supplements; lecithin dietary supplements; nutritional supplements; dietary supplements mainly consisting of seafood extracts in the form of powders, pills, capsules, granules, jellies or liquids; dietary supplements for human beings; dietary fibre; lyophilised food adapted for medical purposes; lyophilized meat adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies Provision of medical and pharmaceutical information via the Internet; provision of medical information relating to benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; analysis and provision of clinical data of patients for diagnostic or treatment purpose; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for diagnostic or treatment purpose; providing medical information; physical examination; providing information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to dieting, nutritional intake or health care; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nutritional consultancy and advisory for preventing and decreasing obesity; provision of information about nutritional consultancy and advisory for preventing and decreasing obesity; dietary and nutritional guidance; nursing care; rental of medical apparatus and instruments
A compound represented by the general formula (V)
A compound represented by the general formula (V)
A compound represented by the general formula (V)
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07C 49/252 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings and other rings
C07C 49/577 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing ether groups, groups, groups, or groups
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes, namely, for cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicines for veterinary purposes for the treatment of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; anesthetic for surgical purposes, sedative and analgesic drugs; vaccines; reagent paper for medical purposes; vitamin preparations; candy, medicated; cough pastilles for pharmaceutical purposes; mint for pharmaceutical purposes; chewing gum for medical purposes; lecithin for medical purposes; greases for medical purposes; cod liver oil; medicinal preparations for the mouth to be applied in the form of capsules; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive medical plasters; bandages for dressings; liquid bandages for skin wounds; breast-nursing pads; cotton swabs for medical use; dental materials, namely, dental sealants, adhesives, amalgams, ceramics, abrasives, cements, alloys, wax, polish; baby diapers; infant diapers; adult diapers; baby diaper covers; infant diaper covers; adult diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; glucose dietary supplements; lecithin dietary supplements; nutritional supplements; dietary supplements mainly consisting of seafood extracts in the form of powders, pills, capsules, granules, jellies or liquids; dietary supplements for humans; dietary fibre to aid digestion; lyophilized food adapted for medical purposes; lyophilized meat adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies being baby foods; food for babies; nutritional supplements for animals; dietary supplements for animals; semen for artificial insemination Beauty salon services; barber shop services; providing bath houses; massage and therapeutic shiatsu massage; chiropractic services; moxibustion; medical treatment of dislocated joints, sprain, bone fractures; bodywork therapy; acupuncture; provision of medical information and information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals via the Internet; provision of medical information relating to benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical products; provision of information on diagnostic, prophylactic and therapeutic properties of pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications via the Internet; online medical counseling services; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for diagnostic or treatment purpose; provision of medical information; physical examination services; providing information about diagnostic, prophylactic and therapeutic properties of pharmaceuticals, medical services and health; consultancy services relating to medical services, diagnostic, prophylactic and therapeutic properties of pharmaceuticals, health and dispensing of medications; consultancy, advisory and provision of information relating to weight reduction diet planning, food nutritional intake and health care; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nutritional consultancy and advisory for preventing and decreasing obesity; provision of information about nutritional consultancy and advisory for preventing and decreasing obesity; dietary and nutritional guidance; animal breeding; veterinary services; beautification for animals, namely, animal grooming; nursing care; rental of medical apparatus and instruments
The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
The problem addressed by the present invention is to provide a novel preparation that contains an anti-PD-1/CD3 bispecific antibody as an active ingredient and that is for the prevention, suppression of symptom development, suppression of recurrence, or treatment of autoimmune diseases, or a graft-versus-host disease (GVHD) or hematological cancer. The invention provides an aqueous pharmaceutical composition and a preparation comprising same. The aqueous pharmaceutical composition contains an anti-PD-1/CD3 bispecific antibody as an active ingredient, and further contains, for example, an acetate buffer, trehalose, L-methionine, polysorbate 80, and sodium chloride. The aqueous pharmaceutical composition can be used for both subcutaneous and intravenous administration in the form of single excipient composition.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
To provide a compound having EP3 agonist activity. A compound represented by general formula (I) (in the formula, all symbols are as defined in the description) or a salt thereof has strong EP3 agonist activity and can therefore be used as an EP3 agonist.
C07D 313/06 - Seven-membered rings condensed with carbocyclic rings or ring systems
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Provided is a prophylactic and/or therapeutic agent for kidney diseases. The present invention provides a prophylactic and/or therapeutic agent for kidney diseases (for example, chronic kidney disease, acute kidney failure, or the like) that contains a compound represented by general formula (I) (wherein all the symbols are as defined in the description) or a salt thereof.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is provided, which is useful as a pharmaceutical ingredient having GBA1 and GCS dual modulatory activity in the prevention and/or treatment of a disease associated with GBA1 and/or GCS, in which all symbols represent the same meaning as the symbols described in the specification. A drug is also provided, which containing, as an active ingredient, a compound having GBA1 and GCS dual modulatory activity in prevention and/or treatment of a disease associated with GBA1 and/or GCS.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
An effective cancer treatment method is disclosed. According to the cancer treatment method, a CD47 inhibitory substance, an immune checkpoint inhibitory substance (for example, an anti-PD-1 antibody), and a standard therapy (for example, a combination therapy in which Bevacizumab or Cetuximab is added to FOLFOX therapy for radically unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a dose-reduced regimen thereof for pancreatic cancer having distant metastasis) are combined. The treatment method is useful for cancer treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A23L 17/30 - Fish eggs, e.g. caviarFish-egg substitutes
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
40.
THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
Inventor
Takayama, Koichi
Yamada, Tadaaki
Yasuhiro, Tomoko
Tanaka, Kohei
Abstract
A therapeutic agent for solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and to be administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination has strong antitumor effect and is therefore useful for treatment of solid cancers.
Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
42.
MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION
Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
An antibody or antigen-binding fragment thereof is disclosed. The antibody or antigen-binding fragment thereof binds to HER2 expressed on a cancer cell or a fragment of the HER2. A HER2-targeting agent containing any of the antibody or antigen-binding fragment thereof, and a pharmaceutical composition containing the HER2-targeting agent are disclosed.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
44.
INFORMATION PROCESSING DEVICE, PROGRAM, AND INFORMATION PROCESSING METHOD
[Problem] To provide an information processing device that is capable of reducing the burden on a user and contributing to improvement in the mental state of the user. [Solution] According to one aspect of the present invention, an information processing device is provided. This information processing device comprises a receiving unit, an extracting unit, and an output unit. The receiving unit receives first mood information pertaining to the mood of a first user. On the basis of the first mood information and reference information, the extracting unit extracts experience diary information which pertains to an experience diary kept by a second user who is different from the first user. The reference information is information indicating the relationship between second mood information about the mood of the second user and the experience diary information. The output unit outputs the experience diary information.
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16Y 20/40 - Information sensed or collected by the things relating to personal data, e.g. biometric data, records or preferences
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represented by general formula (I) (in the formula, all symbols have the same meanings as the symbols described in the description) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity, and is therefore useful as a drug component having potent ABHD6 inhibitory activity in the prevention and/or treatment of diseases associated with ABHD6.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
The present invention addresses the problem of providing a compound having inhibitory activity against DGK α and/or ζ. As a result of diligent study, the inventors of the present invention found, as a substance that can solve the above problem, a compound which has inhibitory activity against DGK α and/or ζ and which is represented by general formula (IY) [where all symbols in the formula have the same meaning as set forth in the specification]. A compound according to the present invention, which is represented by general formula (IY), has inhibitory activity against DGK α and/or ζ, and thus can be used as an active ingredient in an agent for inhibiting the progression of, inhibiting the recurrence of, and/or for treating cancer or infectious diseases, for example.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention addresses the problem of providing a novel drug for preventing cancer, suppressing the progression of a symptom of cancer, suppressing the recurrence of cancer, or treating cancer. As the results of intensive studies, the present inventors focused attention on Allergin-1 that is a target molecule involved in the regulation of cancer immunity, and found a bispecific antibody capable of binding specifically respectively to two different epitopes on the S1 and S2 domains, said domains being the extracellular domains of Allergin-1, as a substance that can solve this problem. The present inventors confirmed that this antibody is useful for preventing cancer, suppressing the progression of a symptom of cancer, suppressing the recurrence of cancer, or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
An antibody that binds to HER2 expressed on a cancer cell or a fragment of the HER2, or an antigen binding fragment thereof are disclosed. Uses of the antibody or antigen binding fragment thereof are disclosed. The antibody or antigen binding fragment thereof is useful to target a HER2 expressing cancer cells. A-pharmaceutical composition containing the antibody or antigen binding fragment thereof is also disclosed.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The problem addressed by the present invention is to provide a method for determining haplotype based on a combination of multiple single nucleotide polymorphisms (SNP) in the human STING1 gene. As a result of in-depth studies by the present inventors, such a method was established, and the present invention was completed. Specifically, the present invention provides a method for determining haplotype based on the combination of four SNP each identified by rs7380824, rs1131769, rs78233829, and rs11554776 in the human STING1 gene.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
53.
NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japan)
Eisai R&D Management Co., Ltd. (Japan)
Ono Pharmaceutical Co., Ltd. (Japan)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japan)
Inventor
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Yamamoto, Takeshi
Wakabayashi, Takeshi
Abstract
An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.
An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/06 - Phosphorus compounds without P—C bonds
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
56.
COMPOSITION FOR OPHTHALMIC USE CONTAINING SEPETAPROST
The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of shelf life of this composition for ophthalmic use. The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w/v) and has a pH within a range from 5 to 8.
Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof. Examples of LPA3 agonists include compounds having a structural formulae (IA) to (IIIA) are disclosed as agonists or antagonist of EDG7 (=LPA3) receptor:
A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof. Examples of LPA3 agonists include compounds having a structural formulae (IA) to (IIIA) are disclosed as agonists or antagonist of EDG7 (=LPA3) receptor:
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
16 - Paper, cardboard and goods made from these materials
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemicals for use in the manufacture of pharmaceuticals;
chemicals for use in the manufacture of cosmetics; chemicals
for use as food additives; chemicals; glue and adhesives for
industrial purposes; plant growth regulating preparations;
fertilizers; ceramic glazings; priming putty; higher fatty
acids; silicon; rare earths; mercury; radium for scientific
purposes; non-metallic minerals; chemical compositions for
developing and printing photographs; reagent paper [not for
medical purposes]; artificial sweeteners; flour and starch
for industrial purposes; synthetic resins, unprocessed;
plastics [raw materials]; groundwood pulp or chemical pulps
for manufacturing purposes. Antistatic preparations for household purposes; de-greasing
preparations for household purposes; rust removing
preparations; stain removing benzine; fabric softeners for
laundry use; laundry bleach; adhesives for affixing false
hair; laundry starch; seaweed gelatine for laundry use
[funori]; adhesives for affixing false eyelashes; breath
freshening preparations; deodorants for animals; paint
stripping preparations; shoe cream; shoe black [shoe
polish]; polishing preparations; soaps and detergents;
dentifrices; cosmetics; perfumery; fragrances; food
flavourings [essential oils]; incense; abrasive paper
[sandpaper]; abrasive cloth; abrasive sand; artificial
pumice stone; polishing paper; false nails; false eyelashes. Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc. Finger guards for medical purposes; pacifiers for babies;
ice bag pillows for medical purposes; triangular bandages;
support bandages; surgical catguts; feeding cups for medical
purposes; dropping pipettes for medical purposes; teats;
medical ice bags; medical ice bag holders; baby bottles;
nursing bottles; contraceptives, non-chemical; artificial
tympanic membranes; prosthetics or fillings materials, not
for dental use; ear plugs for sleeping; ear plugs for
soundproofing; esthetic massage apparatus for commercial
use; medical apparatus and instruments; electric massage
apparatus for household purposes; gloves for medical
purposes; urinals for medical purposes; bed pans; ear picks;
sanitary masks. Pastes and other adhesives for stationery or household
purposes; sealing wax; printers' reglets; printing type;
addressing machines; ink ribbons; automatic stamp affixing
machines; electric staplers for offices; envelope sealing
machines for offices; stamp obliterating machines; drawing
instruments; typewriters; checkwriters; mimeographs; relief
duplicators; paper shredders for office use; franking
machines; rotary duplicators; marking templates; decorators'
paintbrushes; paperboard packaging containers for
pharmaceuticals; containers of paper, for packaging; bags
[pouches] of plastics, for packaging; food wrapping plastic
film for household purposes; garbage bags of paper for
household purposes; garbage bags of plastics for household
purposes; paper patterns; tailors' chalk; banners of paper;
flags of paper; hygienic hand towels of paper; towels of
paper; table napkins of paper; hand towels of paper;
handkerchiefs of paper; shipping tags; printed paper for
lot, other than toy; wrapping paper for medicine dispensing
machine; paper and cardboard; stationery; pamphlets relating
to medicine and pharmaceuticals; magazines relating to
medical services and pharmaceuticals; catalogues relating to
pharmaceuticals and medical services; printed matter;
paintings and calligraphic works; photographs; photograph
stands. Fruit-based, vegetable-based, bean-based or nut-based
snacks; edible oils and fats; milk products; meat; eggs;
fresh, chilled or frozen edible aquatic animals [not live];
frozen vegetables; frozen fruits; processed meat products;
processed seafood products; processed vegetables and fruits;
fried tofu pieces [abura-age]; freeze-dried tofu pieces
[kohri-dofu]; jelly made from devils' tongue root
[konnyaku]; soya milk; tofu; fermented soybeans [natto];
processed eggs; pre-cooked curry stew, stew and soup mixes;
dried flakes of laver for sprinkling on rice in hot water
[ochazuke-nori]; furi-kake [dried flakes of fish, meat,
vegetables or seaweed]; side-dish made of fermented soybean
[name-mono]; preserved pulses. Aromatic preparations for food, not from essential oils;
tea; coffee; cocoa; ice; sweets; confectionery; candies;
pastries; cakes; fondants [confectionery]; bread and buns;
sandwiches; steamed buns stuffed with minced meat
[chuka-manjuh]; hamburgers [sandwiches]; pizzas; hot dog
sandwiches; meat pies; seasonings; condiments; spices; ice
cream mixes; sherbet mixes; unroasted coffee beans; cereal
preparations; chocolate spread; Chinese stuffed dumplings
[gyoza, cooked]; Chinese steamed dumplings [shumai, cooked];
sushi; fried balls of batter mix with small pieces of
octopus [takoyaki]; boxed lunches consisting of rice, with
added meat, fish or vegetables; ravioli; yeast powder; koji
[fermented malted rice]; yeast; baking powder; instant
confectionery mixes; pasta sauce; by-product of rice for
food [sake lees]; gluten for food; flour. Beer; carbonated drinks [refreshing beverages]; soft drinks;
fruit juices; vegetable juices [beverages]; extracts of hops
for making beer; whey beverages. Retail services or wholesale services for foods and
beverages; retail services or wholesale services for dietary
supplements for humans; retail services or wholesale
services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; retail services or
wholesale services for cosmetics, toiletries, dentifrices,
soaps and detergents; retail services or wholesale services
for printed matter; retail services or wholesale services
for paper and stationery; retail services or wholesale
services for measures; retail services or wholesale services
for medical apparatus and instruments; arranging, conducting
and organization of exhibitions for sales promotion of
pharmaceuticals, medical apparatus and instruments;
arranging, conducting and organization of trade fairs for
sales promotion of pharmaceuticals, medical apparatus and
instruments; advertising services relating to pharmaceutical
products; advertising and publicity services; marketing
research in the field of medical services or
pharmaceuticals; business consulting and advisory services
relating to improvement of pharmaceutical productivity;
business consulting and advisory services in the field of
pharmaceuticals; marketing research relating to
pharmaceuticals; compilation and provision of business
statistical information relating to the pharmaceutical
industry; providing information concerning commercial sales
of pharmaceuticals, cosmetics and foods; providing
information concerning commercial sales of health foods,
dietary supplements and healthcare products; business
planning and organization for healthcare business; business
management analysis or business consultancy; business
management; marketing research or analysis; providing
information concerning commercial sales; administrative
services for the referral of medical doctors, dentists,
nurses and pharmacists; employment agency services;
import-export agencies; office functions, namely filing, in
particular documents or magnetic tapes; compilation of
pharmaceutical research information into computer database;
compilation of information into computer databases;
systemization, updating and maintenance of clinical data
relating to clinical trials of pharmaceutical products at
medical institutions and clinical data of patients in
computer database; maintaining records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; updating and maintenance of data in computer
databases; compilation and systemization of information into
computer databases; providing business assistance to others
in the operation of data processing apparatus namely,
computers, typewriters, telex machines and other similar
office machines; reception services for visitors in
buildings [office functions]; publicity material rental;
providing commercial information and advice for consumers in
the choice of products and services; providing employment
information; computational data processing. Acceptance of deposits [including substitute bond issuance]
and acceptance of fixed interval installment deposits; loans
[financing] and discount of bills; domestic exchange
settlement; liability guarantee and acceptance of bills;
securities lending; acquisition and transfer of monetary
claims; safekeeping of valuables including securities and
precious metals [safe deposit services]; exchanging money;
trusteeship of financial futures contracts; trusteeship of
money, securities, monetary claims, personal property, land,
rights on land fixtures, surface rights or lease on land;
agencies for bond subscriptions; foreign exchange
transactions; letter-of-credit related services; brokerage
of credit purchase; venture capital funding; venture capital
fund management; venture capital funding services to
emerging and start-up companies; issuance of tokens of
value; agencies for collecting gas or electric power utility
payments; consigned collection of payment for goods; buying
and selling of securities; trading of securities index
futures; trading of securities options; trading of overseas
market securities futures; agencies for brokerage of
securities, securities index futures, securities options,
and overseas market securities futures; agencies for
brokerage of securities, securities index futures and
securities options in domestic markets; agencies for
brokerage of securities and securities index futures in
overseas markets; agencies for brokerage of forward
agreement of securities, for forward agreement of securities
index futures, for forward agreement of securities options,
spot and forward transaction of securities index futures;
brokerage for securities liquidation; securities
underwriting; securities offering; brokerage services
relating to securities subscription or offering; providing
stock market information; agencies for commodity futures
trading; life insurance brokerage; life insurance
underwriting; agencies for non-life insurance; claim
adjustment for non-life insurance; non-life insurance
underwriting; insurance premium rate computing; management
of buildings; agency services for the leasing or rental of
buildings; leasing or renting of buildings; purchase and
sale of buildings; real estate agency services for the
purchase or sales of buildings; real estate appraisal;
providing information on buildings or land [real estate
affairs]; land management; agency services for the leasing
or rental of land; leasing of land; purchase and sale of
land; real estate agency services for the purchase or sales
of land; providing monetary grants for medical project;
providing monetary grants for research and development of
pharmaceuticals and medical technology; providing monetary
grants for medical research and medical education; providing
project grants for social welfare, healthcare, medical,
education, sport, physical exercise and environmental
conservation programmes; advisory services relating to
financial grants; provision of information relating to
provision of grants; provision of grants; arranging and
organization of charitable fundraising for volunteer and
welfare activities; arranging and organization of
fundraising for charitable activities; providing information
relating to charitable fund raising; charitable fund-raising
services to support medical research; charitable fund
raising; fund raising services. Educational and training services relating to medicine and
pharmaceuticals, and providing information relating thereto;
educational and training services relating to clinical
trials of pharmaceutical products; providing educational and
training services relating to medical services and
pharmaceuticals via cable communication and computer network
communication; educational and instruction services relating
to preventing and decreasing obesity; educational and
training services relating to nutrition, health, health
care, fitness, medical services and pharmaceuticals;
educational and instruction services relating to medical
services; educational and instruction services relating to
environmental issues; educational and instruction services
relating to arts, crafts, sports or general knowledge;
providing information on donation of human corpses for
medical education; arranging of donation of human corpses
for medical education; arranging, conducting and
organization of seminars, symposiums or conferences relating
to medical services, pharmaceuticals, health and health
care; arranging and conducting of workshops or training
relating to health, medical service and pharmaceuticals;
arranging, conducting and organization of seminars,
workshops or training relating to preventing and decreasing
obesity; arranging, conducting and organization of seminars,
workshops or training relating to nutrition, health, health
care, fitness, medical services and pharmaceuticals;
arranging, conducting and organization of seminars,
workshops or training relating to environmental issues;
arranging, conducting and organization of seminars or events
relating to environmental conservation; arranging,
conducting and organization of seminars; providing online
electronic publications relating to medical technologies,
biotechniques or pharmaceuticals; providing electronic
dictionaries and encyclopedias via the internet; providing
electronic publications; services of reference libraries for
literature and documentary records; book rental; online
provision of images, movies, videos, music or texts;
publication of books; providing videos from the internet,
not downloadable; providing digital music from the internet,
not downloadable; production of radio or television programs
relating to medical services, pharmaceuticals, health and
health care; production of radio or television programs;
production of videos relating to medical services,
pharmaceuticals, health and health care [not for movies or
television programs and not for advertising or publicity];
production of videos in the field of education, culture,
entertainment or sports [not for movies or television
programs and not for advertising or publicity];
organization, arranging and conducting of sports
competitions; arranging, conducting and organization of
events for preventing and decreasing obesity; arranging,
conducting and organization of events relating to nutrition,
health, health care, fitness, medical services and
pharmaceuticals for educational purposes; organization of
entertainment events excluding movies, shows, plays, musical
performances, sports, horse races, bicycle races, boat races
and auto races; providing sports facilities; providing
amusement facilities; providing facilities for movies,
shows, plays, music or educational training; rental of
sports equipment; toy rental; translation. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; providing information relating to
testing or research on pharmaceuticals via the internet;
research and development of pharmaceuticals and
biopharmaceuticals for treatment and diagnosis of human
disease; research and testing of pharmaceuticals for gene
analysis; providing information relating to research and
development of pharmaceuticals in response to customers'
request via the internet; providing information about
medical and scientific research in the field of
pharmaceuticals; clinical trials for pharmaceuticals;
conducting clinical trials for pharmaceutical products at
medical institutions; providing information about the
results of clinical trials for pharmaceuticals; testing,
inspection or research on pharmaceuticals, chemicals,
cosmetics or foods and providing information relating
thereto; providing research information and results in the
fields of technology, science and medicine from an online
searchable database; providing information about
environmental conservation; environmental testing and
inspection services; providing information about
environmental testing or research relating to environmental
conservation; research on building construction or city
planning; testing or research on prevention of pollution;
testing or research on electricity; testing or research on
civil engineering; testing, inspection or research on
agriculture, livestock breeding or fisheries; testing or
research on machines, apparatus and instruments; rental of
measuring apparatus; rental of computers; providing computer
programs on data networks; software as a service [SaaS];
electronic storage of records of personal health information
data of individuals such as weight, body fat, body
temperature, number of steps, sleeping hours and blood
pressure; rental of laboratory apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical consultancy and diagnosis via the internet; online
medical counseling services; remote monitoring of patient
health status for medical conditions; analysis and provision
of clinical data of patients for diagnostic or treatment
purpose; providing medical information; physical
examination; providing information about pharmaceuticals,
medical services or health; consultancy services relating to
medical services, pharmaceuticals, health or dispensing of
medications; consultancy, advisory and provision of
information relating to dieting, nutritional intake or
health care; consultancy, advisory and provision of
information relating to health care; managed health care
services; provision of records of personal health
information data such as weight, body fat, body temperature,
number of steps, sleeping hours and blood pressure;
nutritional consultancy and advisory for preventing and
decreasing obesity; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of medical apparatus and instruments.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc; audio and video recordings. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; pharmaceutical research; providing
information relating to pharmaceutical research; providing
information relating to testing or research on
pharmaceuticals via the Internet; research and development
of pharmaceuticals and biopharmaceuticals for treatment and
diagnosis of human disease; research and survey of
pharmaceuticals for gene analysis; providing information
relating to research and development of pharmaceuticals in
response to customers' request via the Internet; providing
information about medical and scientific research in the
field of pharmaceuticals; clinical trials; clinical trials
for pharmaceuticals; conducting clinical trials for
pharmaceutical products at medical institutions; providing
information about the results of clinical trials for
pharmaceuticals; testing, inspection or research on
pharmaceuticals, chemicals, cosmetics or foods and providing
information relating thereto; providing research information
and results in the fields of technology, science and
medicine from an online searchable database; providing
information about environmental conservation; testing and
inspection services relating to environmental conservation;
providing information about testing or research relating to
environmental conservation; research on building
construction or city planning; testing or research on
prevention of pollution; testing or research on electricity;
testing or research on civil engineering; testing,
inspection or research on agriculture, livestock breeding or
fisheries; testing or research on machines, apparatus and
instruments; rental of measuring apparatus; rental of
computers; providing computer programs on data networks;
software as a service [SaaS]; electronic storage of medical
records; electronic storage of records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; electronic data storage; rental of laboratory
apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic Shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the Internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical testing; medical consultancy and diagnosis via the
Internet; online medical counseling services; remote
monitoring of patient health status for medical conditions;
remote monitoring of medical data for medical diagnosis and
treatment; analysis and provision of clinical data of
patients for diagnostic or treatment purpose; providing
medical information; physical examination; providing
information about pharmaceuticals, medical services or
health; consultancy services relating to medical services,
pharmaceuticals, health or dispensing of medications;
consultancy, advisory and provision of information relating
to dieting, nutritional intake or health care; consultancy,
advisory and provision of information relating to health
care; managed health care services; provision of records of
personal health information data such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc; audio and video recordings. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; pharmaceutical research; providing
information relating to pharmaceutical research; providing
information relating to testing or research on
pharmaceuticals via the Internet; research and development
of pharmaceuticals and biopharmaceuticals for treatment and
diagnosis of human disease; research and survey of
pharmaceuticals for gene analysis; providing information
relating to research and development of pharmaceuticals in
response to customers' request via the Internet; providing
information about medical and scientific research in the
field of pharmaceuticals; clinical trials; clinical trials
for pharmaceuticals; conducting clinical trials for
pharmaceutical products at medical institutions; providing
information about the results of clinical trials for
pharmaceuticals; testing, inspection or research on
pharmaceuticals, chemicals, cosmetics or foods and providing
information relating thereto; providing research information
and results in the fields of technology, science and
medicine from an online searchable database; providing
information about environmental conservation; testing and
inspection services relating to environmental conservation;
providing information about testing or research relating to
environmental conservation; research on building
construction or city planning; testing or research on
prevention of pollution; testing or research on electricity;
testing or research on civil engineering; testing,
inspection or research on agriculture, livestock breeding or
fisheries; testing or research on machines, apparatus and
instruments; rental of measuring apparatus; rental of
computers; providing computer programs on data networks;
software as a service [SaaS]; electronic storage of medical
records; electronic storage of records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; electronic data storage; rental of laboratory
apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic Shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the Internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical testing; medical consultancy and diagnosis via the
Internet; online medical counseling services; remote
monitoring of patient health status for medical conditions;
remote monitoring of medical data for medical diagnosis and
treatment; analysis and provision of clinical data of
patients for diagnostic or treatment purpose; providing
medical information; physical examination; providing
information about pharmaceuticals, medical services or
health; consultancy services relating to medical services,
pharmaceuticals, health or dispensing of medications;
consultancy, advisory and provision of information relating
to dieting, nutritional intake or health care; consultancy,
advisory and provision of information relating to health
care; managed health care services; provision of records of
personal health information data such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
62.
AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS
A suppression of postsurgical recurrence and/or metastasis of cancer by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery is disclosed. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, containing a beta-blocker and being administered during a perioperative period of cancer surgery.
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japan)
EISAI R&D MANAGEMENT CO., LTD. (Japan)
ONO PHARMACEUTICAL CO., LTD. (Japan)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japan)
Inventor
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Takado, Yuhei
Matsuoka, Kiwamu
Mizuma, Hiroshi
Yamamoto, Takeshi
Wakabayashi, Takeshi
Ohfusa, Toshiyuki
Abstract
Provided is a compound that has high binding selectivity to α-synuclein aggregates. The present invention relates to a compound represented by formula (I), (II) or (III), a pharmaceutically acceptable salt thereof, or a solvate of the compound or pharmaceutically acceptable salt.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
65.
Compound having KDM5 inhibitory activity and pharmaceutical use thereof
Disclosed are compounds of following formula (I):
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
66.
IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST
A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer includes administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A01K 67/027 - New or modified breeds of vertebrates
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
67.
CANCER TREATMENT AGENT INCLUDING MALT1 INHIBITING DRUG AS ACTIVE INGREDIENT
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate, or a solvate thereof, demonstrates a strong antitumor effect, and thus is useful in treating blood cancer.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
C07D 313/06 - Seven-membered rings condensed with carbocyclic rings or ring systems
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
70.
AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION
New uses of an FF-MAS metabolism inhibitor for protecting and/or regenerating a neuromuscular junction or for treating and/or preventing a disorder of a neuromuscular junction are disclosed. In one aspect, a method for protecting and/or regenerating a neuromuscular junction or a method for treating and/or preventing a disorder of a neuromuscular junction, the method including administering an effective amount of an FF-MAS metabolism inhibitor to a mammal is disclosed. In one aspect, an FF-MAS metabolism inhibitor for use in protecting and/or regenerating a neuromuscular junction or for use in treating and/or preventing a disorder of a neuromuscular junction is disclosed. In one aspect, uses of an FF-MAS metabolism inhibitor for manufacturing an agent for protecting and/or regenerating a neuromuscular junction or for manufacturing an agent for treating and/or preventing a disorder of a neuromuscular junction are disclosed.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention provides a tablet comprising opicapone or a pharmaceutically acceptable salt thereof, having reduced tableting faults during manufacture. It further relates to a tablet comprising opicapone or a pharmaceutically acceptable salt thereof, wherein the tablet comprises particles of opicapone or pharmaceutically acceptable salt thereof having the following particle size, and a manufacturing method thereof:(i) a maximum length D50 value of 45 µm or less, and/or (ii) a maximum length D90 value of 110 µm or less
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Provided is a compound having a GCL inhibitory activity. A compound represented by general formula (I) (all symbols in the formula are as defined in the description) or a salt thereof has GCL inhibitory activity, and therefore is useful for inhibiting progression, inhibiting reoccurrence, and/or treatment of GCL-related diseases such as cancer.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
[in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
[in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed.
Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
C07H 13/12 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group —X—C (=X)—X—, or halides thereof, in which X means nitrogen, oxygen, sulfur, selenium, or tellurium, e.g. carbonic acid, carbamic acid
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorders, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilized food
adapted for medical purposes; lyophilized meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Beauty salon services; barber shop services; providing bath
houses; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo-seifuku]; bodywork therapy;
acupuncture; provision of medical and pharmaceutical
information via the Internet; provision of medical
information relating to benefits, side effects, interactions
of pharmaceuticals and medications; provision of medical
information about pharmaceutical products; medical,
medicinal and pharmaceutical consultancy; advisory services
relating to pharmaceutical products; provision of
information on pharmaceuticals and medical services through
computer databases; medical testing for the collection of
medical information, analysis and provision of medical
information for diagnostic or treatment purposes; medical
consultancy and diagnosis via the Internet; online medical
counseling services; remote monitoring of patient health
status for medical conditions; analysis and provision of
clinical data of patients for diagnostic or treatment
purposes; provision of medical information; physical
examination; providing information about pharmaceuticals,
medical services or health; consultancy services relating to
medical services, pharmaceuticals, health or dispensing of
medications; consultancy, advisory and provision of
information relating to dieting, nutritional intake or
health care; consultancy, advisory and provision of
information relating to health care; managed health care
services; provision of records of personal health
information data such as weight, body fat, body temperature,
number of steps, sleeping hours and blood pressure;
nutritional consultancy and advisory for preventing and
decreasing obesity; provision of information about
nutritional consultancy and advisory for preventing and
decreasing obesity; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of medical apparatus and instruments.
A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
76.
METHOD FOR REMOVING COLOR FROM DRUG SUBSTANCE OF PROTEIN PREPARATION
A method for removing coloration from a drug substance solution of protein preparation, in particular, antibody preparation, a method for preparing drug substance solution of protein preparations including it, as a part thereof, and highly concentrated, colorless drug substance solutions thereof are disclosed. The method removes terminal glycation products causing the coloration in the drug substance solution of protein preparation, in particular, antibody preparation, by anion-exchange chromatography, making it possible to provide colorless drug substance solutions.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines Personal digital assistants; downloadable and recorded application software for use in medical diagnostic, testing, analysis or provision of medical information; downloadable and recorded computer programs for use in medical diagnostic, testing, analysis or provision of medical information; computers; downloadable and recorded computer programs and software for use in medical diagnostic, testing, analysis or provision of medical information; computer hardware; computer systems; computer terminals; computer peripheral devices; downloadable and recorded game programs for home video game machines; downloadable music files; downloadable image files containing medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable video files featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable digital books in the field of medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable electronic newspapers; downloadable electronic publications in the nature of books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare recorded on disc; audio and video recordings featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare Designing of machines, apparatus, instruments including their parts or systems composed of such machines, apparatus and instruments; industrial design services; computer software design, computer programming, or maintenance of computer software relating to medical data; design and development of computer software for use with medical technology; development and creation of computer programmes for data processing; rental of computers and software for data processing; computer software design, computer programming, or maintenance of computer software; database design and development; technological advice being technological consulting relating to computers, automobiles and industrial machines; pharmaceutical research; providing information relating to pharmaceutical research; providing information relating to testing or research on pharmaceuticals via the Internet; research and development of pharmaceuticals and biopharmaceuticals for treatment and diagnosis of human disease; research and survey of pharmaceuticals for gene analysis; providing information relating to research and development of pharmaceuticals in response to customers' request via the Internet; providing information about medical and scientific research in the field of pharmaceuticals; conducting clinical trials for others; clinical trials for pharmaceuticals for others; conducting clinical trials for pharmaceutical products at medical institutions for others; providing information about the results of clinical trials for pharmaceuticals; testing, inspection and research on pharmaceuticals, chemicals, cosmetics or foods and providing information relating thereto; providing medical and scientific research information and results in the fields of technology, science and medicine from an online searchable database; providing information about scientific research in the field of environmental conservation; testing and inspection services relating to scientific research in the field of environmental conservation; providing information about testing or scientific research relating to environmental conservation; rental of measuring apparatus; rental of computers; providing online non-downloadable computer programs on data networks for use in medical diagnostic, testing, analysis or provision of medical information; software as a service [SaaS] featuring software for use in medical diagnostic, testing, analysis or provision of medical information; electronic storage of medical records; electronic storage of records of personal health information data of individuals such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; electronic data storage; rental of laboratory apparatus and instruments Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nursing care; rental of medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
Goods & Services
Designing of machines, apparatus, instruments including their parts or systems composed of such machines, apparatus and instruments; industrial design services; computer software design, computer programming, or maintenance of computer software relating to medical data; design and development of computer software for use with medical technology; development and creation of computer programmes for data processing; rental of computers and software for data processing; computer software design, computer programming, or maintenance of computer software; database design and development; technological advice being technological consulting relating to computers, automobiles and industrial machines; pharmaceutical research; providing information relating to pharmaceutical research; providing information relating to testing or research on pharmaceuticals via the Internet; research and development of pharmaceuticals and biopharmaceuticals for treatment and diagnosis of human disease; research and survey of pharmaceuticals for gene analysis; providing information relating to research and development of pharmaceuticals in response to customers' request via the Internet; providing information about medical and scientific research in the field of pharmaceuticals; conducting clinical trials for others; clinical trials for pharmaceuticals for others; conducting clinical trials for pharmaceutical products at medical institutions for others; providing information about the results of clinical trials for pharmaceuticals; testing, inspection and research on pharmaceuticals, chemicals, cosmetics or foods and providing information relating thereto; providing medical and scientific research information and results in the fields of technology, science and medicine from an online searchable database; providing information about scientific research in the field of environmental conservation; testing and inspection services relating to scientific research in the field of environmental conservation; providing information about testing or scientific research relating to environmental conservation; rental of measuring apparatus; rental of computers; providing online non-downloadable computer programs on data networks for use in medical diagnostic, testing, analysis or provision of medical information; software as a service [SaaS] featuring software for use in medical diagnostic, testing, analysis or provision of medical information; electronic storage of medical records; electronic storage of records of personal health information data of individuals such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; electronic data storage; rental of laboratory apparatus and instruments Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nursing care; rental of medical apparatus and instruments Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines Personal digital assistants; downloadable and recorded application software for use in medical diagnostic, testing, analysis or provision of medical information; downloadable and recorded computer programs for use in medical diagnostic, testing, analysis or provision of medical information; computers; downloadable and recorded computer programs and software for use in medical diagnostic, testing, analysis or provision of medical information; computer hardware; computer systems; computer terminals; computer peripheral devices; downloadable and recorded game programs for home video game machines; downloadable music files; downloadable image files containing medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable video files featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable digital books in the field of medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable electronic newspapers; downloadable electronic publications in the nature of books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare recorded on disc; audio and video recordings featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare
80.
Compound having KDM5 inhibitory activity and pharmaceutical use thereof
Disclosed are compounds of following formula (I):
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines
The present disclosure provides the methods for making 4-[4-cyano-2-({[(2'R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1'-cyclopropan]-2'-yl]carbonyl}amino)phenyl]butanoic acid. The present disclosure also generally relates to intermediates useful in the said methods.
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
The present invention addresses the problem of providing: a method for producing a fluorinated imidazole with a good yield; and a method for producing an imidazole compound having a high optical purity. As a result of diligent research, the inventors of the present invention found that a fluorinated imidazole could be obtained at a high yield by using a compound Y. In addition, the inventors of the present invention found that compound Y having a high optical purity could be obtained by subjecting a salt of compound Y and cinchonidine to a purification process by means of recrystallization. By using compound Y having high optical purity as a production intermediate, it is possible to provide a compound X having a high optical purity as a medicinal drug.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
C07D 453/04 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nursing care; rental of medical apparatus and instruments
85.
COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST ACTIVITY AND PHARMACEUTICAL USE THEREOF
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.
C07D 207/22 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 209/70 - [b]- or [c]-condensed containing carbocyclic rings other than six-membered
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
86.
METHOD FOR TREATING CANCER THROUGH COMBINATION OF CD47 INHIBITOR, IMMUNE CHECKPOINT INHIBITOR, AND STANDARD THERAPY
The present invention addresses the problem of providing an effective cancer treatment method. Provided is a cancer treatment method in which are combined a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody, etc.), and a standard therapy (e.g., combination therapy of bevacizumab or cetuximab added to FOLFOX therapy for unresectable advanced or recurrent colorectal cancer, FOLFIRINOX therapy or a low-dose regimen thereof for pancreatic cancer with distal metastases). The treatment method according to the present invention is useful in cancer treatment.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07C 233/76 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07C 323/29 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides a composition for improving cognitive function that comprises a fish roe lipid preparation. In one embodiment, provided is a composition for improving cognitive function that comprises a fish roe lipid preparation prepared so as to provide about 100 mg or more and less than 300 mg per day of DHA, wherein the cognitive function is the linguistic ability of a subject who takes regular exercise.
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound represented by general formula (I-A) (wherein all symbols are as defined in the description) or a pharmaceutically acceptable salt thereof has an ABHD6-inhibiting activity, and is therefore useful as a medicinal component having a potent ABHD6-inhibiting activity in the prevention and/or treatment of a diseases associated with ABHD6.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure provides a composition for improving the quality of sleep, the composition containing a fish roe lipid preparation and a diacyl glyceryl ether.
A compound of formula (I-a):
A compound of formula (I-a):
A compound of formula (I-a):
wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
95.
SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR
An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
99.
COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST
44 receptor antagonist. The combination according to the present invention exhibits a strong antitumor effect and therefore is useful in cancer treatment.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
(wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 327/48 - Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
